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Abstract
The effectiveness of adenosine-induced flow arrest in surgical clipping for the cerebral aneu-
rysms with difficulties in temporary clip placement to the proximal main trunk has been reported. 
This is the first clinical trial to evaluate the safety and feasibility of adenosine-assisted clipping 
surgery for unruptured cerebral aneurysms (UCAs) in Japan. The inclusion criteria are as fol-
lows: patients over 20 years old, patients who agree to be enrolled in this study after providing 
informed consent, patients who undergo clipping surgery for UCA in our institute, and patients 
in whom the surgeons (T.H. or I.D.) judge that decompression of the aneurysm is effective. The 
primary endpoint is a modified Rankin Scale (mRS) score 30 days after surgery. We plan to enroll 
10 patients in this study. The original protocol of adenosine administration was established in 
this trial. Herein, we present the study protocol.
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Introduction
The prevalence of unruptured cerebral aneurysms 
(UCAs) and the annual rate of UCA rupture in 
Japanese cohort has been reported to be approxi-
mately 3% and 0.9%, respectively.1,2) Considering 
the high mortality in cases of UCA rupture, preven-
tive treatment for UCAs is recommended based on 
the size, shape, and location of UCAs. Surgical 
clipping plays a central role in preventing UCA 
rupture. Decompressing aneurysms and visualizing 
the anatomy around them during surgical clipping 
are important to obliterate aneurysms completely 
and to preserve perforators close to aneurysms. 
Large and giant CAs have been reported to have a 
high treatment-related morbidity rate3) and the 
decompression of aneurysms is necessary for safe 
clipping. The placement of a temporary clip at the 
main trunk proximal to aneurysms is usually 
performed to decompress aneurysms. Large aneu-
rysms, deep aneurysm location, and adjacence to 
the skull base bone can prevent the securing of the 
main trunk proximal to aneurysms, however. Severe 
atherosclerosis of the main trunk proximal to aneu-
rysms may cause insufficient occlusion of the 
proximal main trunk by the temporary clip and 
cerebral infarction due to thrombogenesis. Recently, 
the effectiveness of adenosine-induced transient 
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asystole for cases unsuitable for temporary clip 
placement in surgical clipping has been reported.4–10) 
In Japan, adenosine is approved for various symp-
toms related to complications following head trauma, 
heart failure, muscular dystrophy, acute poliomyelitis, 
cerebral palsy, progressive spinal amyotrophy, 
accommodative asthenopia, tinnitus, hearing loss, 
chronic gastritis, and chronic hepatic disease, and 
adenosine-induced decompression of UCAs is an 
off-label use. The aim of this specific clinical trial 
is to investigate whether adenosine is a safe and 
viable alternative to temporary clip placement in 
clipping surgery for UCAs.
Materials and Methods
Endpoints
The primary endpoint is a modified Rankin Scale 
(mRS) score 30 days after surgery. The secondary 
endpoints are (1) the degree of aneurysm obliteration 
by the clip, (2) the total dosage of adenosine, (3) the 
time between adenosine administration and termi-
nation of clipping, (4) mRS scores at discharge and 
at 90 days after surgery, (5) the prevalence of main-
taining systolic blood pressure at less than 60 mmHg 
for between 30 s and 1 min by adenosine admin-
istration and its duration, (6) adverse events related 
to adenosine (paroxysmal atrial fibrillation [Paf] 
within 24 h after adenosine administration, prolonged 
hypotension of less than 60 mmHg in systolic blood 
pressure for more than 1 min, and the elevation of 
high-sensitivity cardiac troponin T), and (7) other 
adverse events (a reduction of amplitude in the 
motor evoked potential [MEP] and somatosensory 
evoked potential [SEP], new infarction detected by 
magnetic resonance imaging on the day after surgery).
Inclusion criteria
(1) Patients over 20 years old; (2) patients who 
agree to be enrolled in this study after providing 
informed consent; (3) patients who undergo clipping 
surgery for UCA in our institute; (4) patients in 
whom the surgeons (T.H. or I.D.) judge that decom-
pression of the aneurysm is effective for one of the 
following reasons: ≥7 mm in aneurysm size; ≥4 mm 
in neck size (≤2 in dome/neck ratio); adhesion of 
branches, perforators, or veins to the aneurysm; 
being buried in the brain; atherosclerosis of the 
aneurysm; and existence of a daughter sac.
Exclusion criteria
(1) Significant coronary artery stenosis; (2) past 
history of ischemic heart disease; (3) moderate and 
severe aortic valve stenosis; (4) obstructive hyper-
trophic cardiomyopathy; (5) history of Paf; (6) 
atrioventricular (AV) block; (7) asthma; (8) chronic 
obstructive pulmonary disease; (9) patients over 80 
years old; (10) pregnant or breastfeeding women; 
(11) patients who simultaneously undergo clipping 
surgery for multiple aneurysms in a single operation; 
and (12) patients who are deemed to be uninterested 
or to have possible interruptions in the assessment 
by the physician.
Study design
This is a single-center, single-arm study to eval-
uate the safety and feasibility of adenosine-assisted 
clipping surgery for UCAs. This study was approved 
by the Okayama University Certified Review Board 
(approved number: CRB20-003) and was registered 
in the Japan Registry of Clinical Trials (jRCT, regis-
tration no. jRCTs061200023).
Recruitment and setting
Figure 1 shows the flow chart of recruitment for 
this study. Screening includes blood examination, 
electrocardiogram, chest X-ray, spirometry, high- 
sensitivity cardiac troponin T, and cardiovascular 
medicine and anesthesiology consultations. Coronary 
artery stenosis is screened by stress electrocardio-
gram.
Treatment and assessment schedule
The protocol of adenosine administration was 
established to maintain systolic blood pressure at 
less than 60 mmHg for between 30 s and 1 min in 
this study (Fig. 2). In cases of cessation of adenosine 
administration, decompression of the aneurysm is 
performed by applying a temporary clip to the 
proximal artery to the aneurysm. If redoing the clip 
application is needed, a temporary clip is used to 
decompress the aneurysm without a second admin-
istration of adenosine. Undiluted adenosine is rapidly 
Fig. 1 The flow chart of recruitment in this study 
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administered through a central venous catheter in 
a manual fashion. As adenosine is more likely to 
cause asystole or bradycardia due to sinus arrest 
or AV block, electrocardiogram, arterial pressure, 
and central venous pressure are carefully monitored 
during the operation and transcutaneous pacing and 
related inotrope are prepared. Both MEP and SEP 
monitoring are performed during the procedure and 
amplitude less than 30% compared to the control 
in MEP and less than 50% in SEP are judged as 
adverse events. The assessment schedule after surgery 
is presented in Fig. 3. High-sensitivity cardiac 
troponin T is checked to evaluate myocardial isch-
emia on postoperative day 1. The elevation of 
high-sensitivity cardiac troponin T is defined as 
more than 0.014 ng/mL on postoperative day 1, and 
an increase of more than 20% compared to the 
preoperative value.11) Electrocardiogram is monitored 
24 h after the operation to detect Paf. Brain magnetic 
resonance imaging is performed to assess ischemic 
lesions on postoperative day 1. The degree of aneu-
rysm obliteration by the clip is evaluated by 
three-dimensional computed tomography angiography 
on postoperative days 4–7, and is divided into three 
categories: complete clipping, residual neck, and 
residual dome.
Statistical considerations
We plan to enroll 10 patients in this study, in 
light of the number of annual cases who undergo 
clipping for UCAs in our institute and the survey 
period. In this study, statistical description is mainly 
performed due to the small sample size. The point 
estimate and 95% confidence interval are calculated 
as an analysis of the primary outcome. The number 
of adverse events from the point of adenosine 
administration to the day after surgery is aggregated 
for the safety assessment.
Discussion
Adenosine is a nucleoside analogue that binds to 
cardiac A1 receptors and his binding causes AV 
nodal blockage and bradycardia. To achieve hypo-
tension 10–20 s after adenosine bolus injection and 
to recover normotension promptly due to a short 
half-life of 0.6–20 s is advantageous for the decom-
pression of aneurysms in clipping surgery.8) Groff 
et al. first reported adenosine use in clipping surgery 
for a basilar artery aneurysm.12) Recently, several 
studies have reported the effectiveness of adenos-
ine-induced flow arrest in surgical clipping for 
aneurysms with challenging temporary clip place-
ments to the proximal main trunk due to large 
aneurysm size, deep aneurysm location, adjacence 
to the skull base bone, premature aneurysm rupture, 
and severe atherosclerosis of the main trunk.5,6,9,13) 
The American Heart Association/American Stroke 
Association includes adenosine for temporary cardiac 
arrest as a technical advance in the guidelines for 
the management of patients with UCAs.14)
The use of adenosine to decompress aneurysms 
is not yet approved and this is the first clinical 
trial to evaluate the safety and feasibility adenos-
ine-assisted clipping surgery for UCAs in Japan. 
This study investigates whether adenosine is a 
viable alternative to temporary clip placement in 
clipping surgery. As it is possible that cardiopul-
monary function is damaged in patients with 
ruptured aneurysms, this study only included 
patients with UCAs. Most patients with UCAs have 
a preoperative mRS score of 0. When considering 
surgical clipping for UCAs as a preventive treat-
ment, preserving the preoperative mRS score after 
surgery is one of the goals of UCA treatment. As 
such, the mRS score 30 days after adenosine use 
was set as a primary endpoint in this study. The 
original protocol of adenosine administration was 
established in this trial. This protocol was based 
on previous reports4–9,13) and advice from anesthe-
siologists and cardiovascular medicine clinicians. 
To determine the optimal dose of adenosine in 
Japanese patients, it is important to assess the 
adequacy of this protocol. Some papers reported 
temporary arrythmia and the elevation of troponin 
T as adverse events.4,5,7–9) In addition to these adverse 
Fig. 2 The protocol of adenosine administration 
Fig. 3 Post-surgical assessment schedule 
Neurol Med Chir (Tokyo) 61, July, 2021
T. Hishikawa et al.396
cardiac events, the ischemic influence of adenosine- 
induced hypotension on the central nervous system 
during surgery is monitored with both SEP and 
MEP in this study.
This study is the first step in adenosine-assisted 
clipping surgery for UCAs. If adenosine use is 
established as a viable alternative to the placement 
of a temporary clip, adenosine could be utilized in 
aneurysms that present challenges in the placement 
of a temporary clip.
Trial status
The trial is currently in the recruitment phase. 
Recruitment commenced in October 2020 and data 
collection will be completed by September 30, 2023.
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